Computationally identified novel agonists for GPRC6A.
New insights into G protein coupled receptor regulation of glucose metabolism by β-cells, skeletal muscle and liver hepatocytes identify GPRC6A as a potential therapeutic target for treating type 2 diabetes mellitus (T2D). Activating GPRC6A with a small molecule drug represents a potential paradigm-...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5912754?pdf=render |
id |
doaj-41e46d649cdc4ea6bc5090886a6ba655 |
---|---|
record_format |
Article |
spelling |
doaj-41e46d649cdc4ea6bc5090886a6ba6552020-11-25T02:08:05ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01134e019598010.1371/journal.pone.0195980Computationally identified novel agonists for GPRC6A.Min PiKaran KapoorRuisong YeDong-Jin HwangDuane D MillerJeremy C SmithJerome BaudryL Darryl QuarlesNew insights into G protein coupled receptor regulation of glucose metabolism by β-cells, skeletal muscle and liver hepatocytes identify GPRC6A as a potential therapeutic target for treating type 2 diabetes mellitus (T2D). Activating GPRC6A with a small molecule drug represents a potential paradigm-shifting opportunity to make significant strides in regulating glucose homeostasis by simultaneously correcting multiple metabolic derangements that underlie T2D, including abnormalities in β-cell proliferation and insulin secretion and peripheral insulin resistance. Using a computational, structure-based high-throughput screening approach, we identified novel tri-phenyl compounds predicted to bind to the venus fly trap (VFT) and 7-transmembrane (7-TM) domains of GPRC6A. Experimental testing found that these compounds dose-dependently stimulated GPRC6A signaling in a heterologous cell expression system. Additional chemical modifications and functional analysis identified one tri-phenyl lead compound, DJ-V-159 that demonstrated the greatest potency in stimulating insulin secretion in β-cells and lowering serum glucose in wild-type mice. Collectively, these studies show that GPRC6A is a "druggable" target for developing chemical probes to treat T2DM.http://europepmc.org/articles/PMC5912754?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Min Pi Karan Kapoor Ruisong Ye Dong-Jin Hwang Duane D Miller Jeremy C Smith Jerome Baudry L Darryl Quarles |
spellingShingle |
Min Pi Karan Kapoor Ruisong Ye Dong-Jin Hwang Duane D Miller Jeremy C Smith Jerome Baudry L Darryl Quarles Computationally identified novel agonists for GPRC6A. PLoS ONE |
author_facet |
Min Pi Karan Kapoor Ruisong Ye Dong-Jin Hwang Duane D Miller Jeremy C Smith Jerome Baudry L Darryl Quarles |
author_sort |
Min Pi |
title |
Computationally identified novel agonists for GPRC6A. |
title_short |
Computationally identified novel agonists for GPRC6A. |
title_full |
Computationally identified novel agonists for GPRC6A. |
title_fullStr |
Computationally identified novel agonists for GPRC6A. |
title_full_unstemmed |
Computationally identified novel agonists for GPRC6A. |
title_sort |
computationally identified novel agonists for gprc6a. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2018-01-01 |
description |
New insights into G protein coupled receptor regulation of glucose metabolism by β-cells, skeletal muscle and liver hepatocytes identify GPRC6A as a potential therapeutic target for treating type 2 diabetes mellitus (T2D). Activating GPRC6A with a small molecule drug represents a potential paradigm-shifting opportunity to make significant strides in regulating glucose homeostasis by simultaneously correcting multiple metabolic derangements that underlie T2D, including abnormalities in β-cell proliferation and insulin secretion and peripheral insulin resistance. Using a computational, structure-based high-throughput screening approach, we identified novel tri-phenyl compounds predicted to bind to the venus fly trap (VFT) and 7-transmembrane (7-TM) domains of GPRC6A. Experimental testing found that these compounds dose-dependently stimulated GPRC6A signaling in a heterologous cell expression system. Additional chemical modifications and functional analysis identified one tri-phenyl lead compound, DJ-V-159 that demonstrated the greatest potency in stimulating insulin secretion in β-cells and lowering serum glucose in wild-type mice. Collectively, these studies show that GPRC6A is a "druggable" target for developing chemical probes to treat T2DM. |
url |
http://europepmc.org/articles/PMC5912754?pdf=render |
work_keys_str_mv |
AT minpi computationallyidentifiednovelagonistsforgprc6a AT karankapoor computationallyidentifiednovelagonistsforgprc6a AT ruisongye computationallyidentifiednovelagonistsforgprc6a AT dongjinhwang computationallyidentifiednovelagonistsforgprc6a AT duanedmiller computationallyidentifiednovelagonistsforgprc6a AT jeremycsmith computationallyidentifiednovelagonistsforgprc6a AT jeromebaudry computationallyidentifiednovelagonistsforgprc6a AT ldarrylquarles computationallyidentifiednovelagonistsforgprc6a |
_version_ |
1724927639690412032 |